Navigating the Evolving Terrain of False Claims Act: Circuit Splits, Causation Complexities, and Whistleblower Triumphs

Published January 3, 2023 In the ever-evolving landscape of False Claims Act (FCA) cases, recent decisions by the Eighth and Sixth Circuits have ignited a circuit split, particularly concerning the interpretation of the anti-kickback statute. The rulings in United States ex rel. Cairns v. D.S. Medical, LLC, and United States ex rel. Martin v. Hathaway, et al., established that proving “but-for” causation is crucial to … Continue reading Navigating the Evolving Terrain of False Claims Act: Circuit Splits, Causation Complexities, and Whistleblower Triumphs

Supreme Court Grapples with Divisions Over Purdue Pharma Bankruptcy Deal Shielding Sacklers from Liability (with Updates)

The justices of the Supreme Court found themselves in a contentious divide on Monday regarding a highly contested bankruptcy settlement involving Purdue Pharma. The settlement aims to allocate billions of dollars to address the opioid epidemic, with the trade-off being the protection of the wealthy Sackler family from civil lawsuits linked to the crisis. Continue reading Supreme Court Grapples with Divisions Over Purdue Pharma Bankruptcy Deal Shielding Sacklers from Liability (with Updates)

Virginia Localities Take on Pharmaceutical Giants in Lawsuits Over Soaring Insulin Costs

The lawsuits filed by Virginia localities against insulin manufacturers and PBMs mark a significant step in the ongoing legal battles over rising drug prices. As the legal proceedings unfold, the outcomes may have far-reaching implications for the pharmaceutical industry and the broader healthcare landscape in the United States. The focus on alleged collusion and artificial price hikes brings attention to the complex dynamics between drug manufacturers, pharmacy benefit managers, and the impact on patients relying on life-saving medications. Continue reading Virginia Localities Take on Pharmaceutical Giants in Lawsuits Over Soaring Insulin Costs